Mainz Biomed NV (MYNZ), a leader in molecular genetics diagnostics, announced on Tuesday the commencement of the eAArly DETECT 2 feasibility study. This initiative aims to advance its cutting-edge colorectal cancer (CRC) screening test. The study is poised to involve about 2,000 participants considered to be at average risk, with the objective of confirming previous findings related to the detection of advanced adenomas, precancerous polyps, and early-stage colorectal cancer.
The eAArly DETECT 2 study leverages an integration of mRNA biomarkers, an AI-driven algorithm, and a Fecal Immunochemical Test (FIT) to improve the precision and sensitivity of CRC diagnostics. The initiative focuses on assessing the efficacy of these biomarkers in identifying advanced adenomas and early-stage CRC within a broad demographic. Enrollment is anticipated to conclude by the latter half of 2025, with initial results expected by the fourth quarter of the same year.
These biomarkers, acquired from Sherbrooke University in 2022, have demonstrated promising capabilities in pinpointing curable adenomas and actionable early-stage CRC. Based on the outcomes of this study, Mainz Biomed intends to finalize the methodologies for its ReconAAsense pivotal study, proposed to commence in 2026.
This innovative CRC screening test holds the potential to revolutionize colorectal cancer prevention through early detection, significantly impacting how screenings are conducted. Meanwhile, Mainz Biomed's stock (MYNZ) is currently trading at $4.74, reflecting a decrease of 1.67%.
